MedTrace Logo

Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome

NCT03031821 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2024-10-04

No results posted yet for this study

Summary

This is a multi-centre, double-blind, randomized phase III trial comparing metformin to placebo in patients with advanced prostate cancer starting (or have recently started) androgen deprivation therapy (ADT).

Conditions

Interventions

DRUG

Metformin

Metformin Duration: 18 months 850 mg PO OD x 30 days then 850 mg PO BID for duration

DRUG

Placebo Oral Tablet

Placebo Oral Tablet Duration 18 months 1 tablet (850 mg) PO OD x 30 days then 1 tablet PO BID for duration

Sponsors & Collaborators

  • Prostate Cancer Canada

    collaborator OTHER

  • British Columbia Cancer Agency

    collaborator OTHER

  • BC Cancer Foundation

    collaborator OTHER

  • Canadian Urologic Oncology Group

    lead OTHER

Principal Investigators

  • Bernie Eigl, MD · British Columbia Cancer Agency

  • Nawaid Usmani, MD · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-12
Primary Completion
2023-11-24
Completion
2023-11-24

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03031821 on ClinicalTrials.gov